MAPT and Alzheimer disease: Increasing evidence, however, has revealed that stroke and AD share many hallmark pathophysiological alterations, including overactivations of glutamatergic N-methyl-D-aspartate (NMDA) receptors (NMDARs), increases in intracellular free Ca2+ ([Ca2+]i), disruptions of energy metabolism, excitotoxicity-induced neuronal loss, programmed cell death, synaptic/neural network impairments, neurovascular damage, neuroinflammation, Aβ/tau deposition, and progressive psychological/cognitive decline [2, 11–15].